Renal Division, Department of Medicine, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York 10467
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We have previously shown that estradiol suppresses the synthesis
of type I collagen by murine mesangial cells grown in the presence of
serum via activation of the transcription factor activator protein-1
(AP-1). We hypothesized that estradiol upregulates AP-1 via activation
of the mitogen-activated protein (MAP) kinase cascade, a signal
transduction pathway that regulates AP-1 activity. Estradiol (1010 to
10
7 M) upregulated the MAP
kinase pathway in murine mesangial cells grown in the presence of serum
in a dose-dependent manner. Activation was evident by 1 min, peaked at
10 min, and was completely dissipated by 2 h. In contrast, estradiol
had no significant effect on total (phosphorylated + unphosphorylated)
p44 extracellular signal-related protein kinase (ERK) or p42 ERK.
Nuclear extracts isolated from mesangial cells treated with estradiol
showed increased binding to a consensus sequence AP-1 binding
oligonucleotide in gel shift assays. In contrast, nuclear extracts from
cells exposed to PD-98059, a highly selective inhibitor of MAP
kinase-ERK kinase 1 (MEK1) and MEK2, showed reduced binding. In
addition, PD-98059 antagonizes the enhanced binding induced by
estradiol. Estradiol (10
9
M) suppressed mesangial cell type I collagen synthesis (37.8 ± 2.4%, expressed as a percentage of control values,
P < 0.001 vs. control). In contrast,
PD-98059 increased type I collagen synthesis (344.6 ± 98.8, P < 0.01) and reversed the
suppression of type I collagen synthesis induced by estradiol. The
effects of estradiol, PD-98059, and PD-98059 plus estradiol on type I collagen protein synthesis were closely paralleled by their effects on
steady-state levels of mRNA for the
1 chain of type I collagen. These data suggest that estradiol suppresses type I collagen synthesis via upregulation of the MAP kinase cascade, leading to stimulation of
AP-1 activity.
gender; sex hormones; matrix proteins; glomerular mesangium; mitogen-activated protein kinase
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
WE HAVE PREVIOUSLY SHOWN that physiological
concentrations of estradiol suppress type I collagen synthesis by
cultured mesangial cells grown in the presence of serum (17, 19, 25,
29-31). However, neither the
1 (I) nor the
2 (I) collagen genes contain an
estrogen response element. We determined that activation of the
transcription factor activator protein-1 (AP-1) mediates the suppressive effect of estradiol on type I collagen (29). In this
regard, estradiol was shown to increase the steady-state message for
c-fos, a component of the heterodimer
that constitutes AP-1 (29). The c-fos
transcription is upregulated by activation of the signal transduction
cascade known as the mitogen-activated protein (MAP) kinase pathway (3,
14). Because estradiol activates this pathway in several other cell
types (7, 8, 21, 27, 32), we postulated that estradiol suppresses type
I collagen synthesis by murine mesangial cells by enhancing AP-1
activity via activation of the MAP kinase pathway.
![]() |
METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Isolation and characterization of murine mesangial cells. Mesangial cells were isolated from kidneys of 8- to 10-wk-old naive male SJL/J (H-2S) mice by differential glomerular sieving. Studies were performed on an immortalized, differentiated murine mesangial cell line transformed with nonreplicating, noncapsid-forming SV40 virus (strain Rh 911). The cells express receptors for angiotensin II (ANG II) and stain positive for Thy-1 antigen, desmin, vimentin, and types I and IV collagens but fail to bind antibody directed against a proximal tubular antigen. To exclude the possibility that SV40 transformation per se might influence our results, replicate studies were performed with nontransformed mesangial cells, passages 5-7. Cells were grown in RPMI 1640 medium (GIBCO Laboratories, Grand Island, NY) containing 10% fetal calf serum (FCS, GIBCO) and 1% penicillin-streptomycin (Sigma Chemical, St. Louis, MO). Results obtained with transformed and nontransformed cells were identical, and the data have been combined.
Western blotting.
Mesangial cells were plated on six-well plates (Becton Dickenson,
Franklin Lakes, NJ) and grown in phenol red-free DMEM medium supplemented with 10% FCS (GIBCO). Cells were grown to confluency and
growth arrested before the experiments. The final estradiol concentration in the medium was
<1011 M (manufacturer's
specifications). Cells were exposed to 17
-estradiol (10
10 to
10
7 M, Sigma),
17
-estradiol (10
7 M), a
time-dependent mixed agonist-antagonist of 17
-estradiol, ICI-182780,
a high-affinity estrogen receptor antagonist (Tocris Cookson, St.
Louis, MO), PD-98059 (50 or 100 µM), a highly selective inhibitor of
MAP kinase-extracellular signal-regulated protein kinase (ERK) 1 (MEK1) and MEK2 (Calbiochem, La Jolla, CA), genistein (18 µM), a nonselective tyrosine kinase inhibitor (Sigma), sodium orthovanadate (1 mM), a tyrosine phosphatase inhibitor (Sigma), platelet-derived growth factor (PDGF)-AB (10 ng/ml; Upstate
Biotechnology, Lake Placid, NY), ANG II
(10
6 M, Sigma), or control
medium for the indicated time periods. In studies in which we measured
type I collagen secreted in the medium, cells were grown in the
presence of
-aminopropionitrile (80 µg/ml) with or without
ascorbic acid (50 µg/ml, Sigma). In addition, the medium contained a
metalloproteinase inhibitor [1,10-phenanthroline (10 µM)]
and a commercial protease inhibitor cocktail containing serine,
cysteine, and aspartic protease inhibitors, and an aminopeptidase inhibitor (Sigma).
Preparation of nuclear extracts. Mesangial cells were scraped into PBS and pelleted by centrifuging at 3,000 g for 10 min at 4°C (28). The cells were resuspended in hypotonic buffer (in mM, 10 HEPES, pH 7.9, 1.5 MgCl2, 10 KCl, 0.2 phenylmethylsulfonyl fluoride, and 0.5 mM dithiothreitol, Sigma), recentrifuged at 3,000 g for 5 min, resuspended in the hypotonic buffer, and allowed to swell for 10 min on ice. The cells were homogenized in a glass Dounce homogenizer. Nuclei were collected by centrifuging at 3,300 g for 15 min. The nuclear pellet was resuspended in low-salt buffer (20 mM HEPES, 2% glycerol, 1.5 mM MgCl2, 0.02 M KCl, 0.2 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, and 0.5 mM dithiothreitol, Sigma). While being stirred gently, a volume of high-salt buffer (1.2 M KCl) equal to one-half the packed nuclear volume was added dropwise. The protein concentration was measured by colorimetric assay (Bio-Rad, Hercules, CA).
Electrophoretic mobility shift assay.
Nuclear extracts (4 µg) were mixed with 2 mg of poly(dI:dC) in 20 µl of a reaction buffer consisting of 25 mM HEPES, pH 7.5, 1.2 mM
dithiothreitol, 4 mM MgCl2, 150 mM
NaCl, 5% glycerol, 0.005% bromphenol blue, and 0.05% Nonidet P-40
(Sigma) (28). The mixture was incubated on ice for 15 min followed
by addition of 10 fmol of
32P end-labeled AP-1 consensus
binding sequence oligonucleotide (Promega, Madison, WI) (nucleotide
sequence: 5'-CGCTTGATGAGTCAGCCGGAA-3'). Incubation was
continued for 30 min. The incubation mixture was subjected to
electrophoresis on a 6% polyacrylamide gel in Tris-glycine buffer. The
gels were dried, and autoradiography was performed at 70°C
with an intensifying screen. Bands were quantitated by laser
densitometry (Molecular Dynamics, model 300S). Competition experiments
were performed with a 200-fold excess of unlabeled AP-1 consensus
binding sequence oligonucleotide.
Messenger RNA for type I collagen.
The steady-state message for the
1 chain of procollagen type I
was evaluated by dot-blot analysis. Mesangial cells were grown as
previously described and exposed to the indicated agents for 48 h.
After extraction of total RNA (RNaid PLUS Kit, Bio 101, Vista, CA),
100-mg aliquots were dissolved in diethyl pyrocarbonate-treated water
and a mixture of formaldehyde and 20× saline-sodium citrate (SSC)
in equal volumes. This solution was heated for 15 min at 65°C to
denature the RNA. The material was then dot blotted at various
concentrations onto nitrocellulose membranes (Bio-Rad dot-blot
apparatus). The blotted membranes were heated at 80°C for 1.5 h.
The cDNA probe for the
1 chain
of human type I collagen (ATCC 61322, Rockville, MD) (11) was prepared
by the Rad-Prime Kit (Life Technologies, Gaithersburg, MD) using 25 ng
of DNA. The probe was heated for 5 min at 100°C and kept on ice
before use. Prehybridization and hybridization of the labeled probe
with the RNA fixed to the nitrocellulose filter was accomplished in a
solution of SDS, termanide, Denhardt, 20× saline-sodium
phosphate-EDTA (all from Sigma) and
H2O at 42°C.
Prehybridization was done for 1.5 h, and hybridization was accomplished
overnight. After hybridization, the filters were washed twice in
2× SSC and 0.1% SDS at room temperature and then with 0.2% SSC
and 0.1% SDS at 55°C for 45 min. Filters were then
autoradiographed using an intensifying screen. Filters were stripped
with a solution consisting of Tris · HCl (5 mM), EDTA
(2 mM), and 0.1× Denhardt solution, and reprobed with
glyceraldehyde-3-phosphate dehydrogenase (Oncogene Research Products,
Cambridge, MA) to correct for variations in RNA loading.
Statistics. For each individual experiment, the mean of replicate determinations was calculated. Data are given as means ± SE. Comparisons among groups were performed with analysis of variance with Scheffé's correction or Student's two-tailed t-test for independent variables. Statistical significance was defined using an overall type I error of 0.05.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In control mesangial cells grown in the presence of 10% FCS, the ratio
of phosphorylated p42 ERK to phosphorylated p44 ERK was 2.8 ± 0.2 to 1. Estradiol upregulated phosphorylated p44 ERK and p42 ERK in a
dose-dependent manner (1010
to 10
7 M,
n = 10;
Fig. 1). Cells exposed to physiological
concentrations of estradiol
(10
9 M) for 5 min showed an
increase in phosphorylated p44 ERK (270.3 ± 24.0%, expressed as
percentage of control values, P < 0.001 vs. control). The maximum increase in p44 ERK was seen with
10
7 M estradiol (476.9 ± 42, P < 0.001). Physiological
concentrations of estradiol
(10
9 M) also increased
phosphorylated p42 ERK (350.1 ± 61.3, P < 0.001). The maximum increase in
phosphorylated p42 ERK was seen with
10
7 M estradiol (743.0 ± 118.0, P < 0.001). In
contrast, estradiol (10
10
to 10
7 M) had no
significant effect on total (phosphorylated + unphosphorylated) p44 ERK
or p42 ERK (not shown).
|
ICI-182780 (106 M), a
high-affinity estrogen receptor antagonist, reversed the activation of
MAP kinase induced by estradiol (10
7 M) [p44 ERK 97.5 ± 9.3 vs. 476.9 ± 42.2, P not
significant (NS) vs. control, P < 0.001 vs. estradiol; p42 ERK 91.8 ± 12.4 vs. 742.9 ± 118.0, P NS vs. control,
P < 0.001 vs. estradiol],
whereas ICI-182780 alone had no effect (p44 ERK 89.8 ± 7.9; p42 ERK 88.0 ± 8.7, P NS vs.
control; Fig. 1). 17
-Estradiol
(10
7 M), a time-dependent
mixed agonist-antagonist of 17
-estradiol, had only a minor effect on
MAP kinase, which did not achieve statistical significance (p44 ERK
126.5 ± 12.3, P NS vs. control;
p42 ERK 159.2 ± 21.5, P NS vs.
control; Fig. 1).
Activation of the MAP kinase pathway by estradiol
(107 M) was already evident
by 1 min (p44 ERK 208.9 ± 22.1%, expressed as percentage
of control values, P < 0.001 vs.
control; p42 ERK 200.6 ± 30.1, P < 0.003;
n = 11; Fig.
2). The peak response was observed at 10 min (p44 ERK 1,670.2 ± 714.4, P < 0.0001; p42 ERK 1,243.6 ± 152.2, P < 0.001) but completely dissipated
by 2 h (Fig. 2).
|
We also assessed the effects of estradiol
(107 M, 10-min exposure) on
mitogen-stimulated MAP kinase activity in serum-starved mesangial cells
(n = 3; Fig. 3). In the
absence of serum, estradiol had no effect on basal p44 or p42 ERK
phosphorylation but reversed the stimulatory effects of PDGF-AB (10 ng/ml) and of ANG II (10
6
M) on ERK phosphorylation. Total (unphosphorylated + phosphorylated ERK) was not changed by any of these agents (data not shown).
|
We measured the effects of PD-98059 (50 µM), a highly selective
inhibitor of MEK1 and MEK2, on estradiol-induced activation of p44 and
p42 ERK (n = 3), upregulation of AP-1
activity (n = 3), and suppression of
type I collagen synthesis (n = 6) in
murine mesangial cells (Fig.
4,
A, B,
and C1). As expected, PD-98059 suppressed basal MAP kinase activity (p44 ERK 23.6 ± 9.4; p42 ERK
38.6 ± 10.8, P < 0.001 vs.
control; Fig. 4A). PD-98059 returned estradiol (107
M)-stimulated MAP kinase activity to control levels (p44 ERK 86.0 ± 35.9 vs. 344.6 ± 56.0, P NS vs.
control, P < 0.01 vs. estradiol; p42
ERK 111.4 ± 21.6 vs. 495.3 ± 14.8, P NS vs. control,
P < 0.01 vs. estradiol).
|
Nuclear extracts isolated from mesangial cells exposed to estradiol
(107 M) for 4 h showed
increased binding to a consensus AP-1 binding sequence oligonucleotide
in gel shift assays (180.1 ± 11.9%, expressed as percentage of
control values, n = 3, P < 0.001 vs. control; Fig.
4B). In contrast, nuclear extracts
exposed to PD-98059 (50 µM) for 4 h showed reduced binding to the
AP-1 oligonucleotide (31.2 ± 5.0, P < 0.001 vs. control). PD-98059
returned estradiol-stimulated nuclear extract binding to control levels
(102.1 ± 7.9 vs. 180.1 ± 11.9, P NS vs. control,
P < 0.001 vs. estradiol,
P < 0.001 vs. PD-98059).
Estradiol (107 M)
suppressed mesangial cell type I collagen synthesis (23.9 ± 5.1%,
expressed as percentage of control values, n = 6, P < 0.001 vs. control; Fig.
4C1). In contrast, PD-98059 (50 µM) increased mesangial cell type I collagen synthesis (195.4 ± 18.8, P < 0.001 vs. control). When
cells were exposed to both estradiol and PD-98059, type I collagen
synthesis returned to control levels (91.7 ± 1.2 vs. 23.9 ± 5.1, P NS vs. control,
P < 0.001 vs. estradiol; Fig.
4C1).
Because PD-98059 in a concentration of 50 µM did not depress
estradiol (107
M)-stimulated MAP kinase activity below control levels (Fig. 4A), we repeated our studies using a
higher concentration of PD-98059 (100 µM) and a lower concentration
of estradiol (10
9 M). At
these concentrations, both PD-98059 alone and PD-98059 plus estradiol
raised type I collagen synthesis above control levels (PD-98059 344.6 ± 96.8, P < 0.01 vs. control;
PD-98059 + estradiol 327.0 ± 68.6, P < 0.01 vs. control,
P NS vs. PD-98059; estradiol 37.8 ± 2.4, P < 0.001 vs. control;
Fig. 4C2). The effects of estradiol,
PD-98059, and PD-98059 plus estradiol on collagen I protein synthesis
were closely paralleled by their effects on steady-state levels of mRNA
for the
1 chain of type I
collagen (Fig. 4C3).
Estradiol-induced suppression of type I collagen synthesis was completely reversed by ICI-182780 (97.9 ± 2.8, P NS vs. control), whereas ICI-182780 alone had no effect on type I collagen synthesis (96.2 ± 3.2, P NS vs. control). Estradiol suppressed type I collagen synthesis to the same degree in cells grown in the presence or absence of ascorbic acid (data not shown).
We also examined the effects of other inhibitors and activators of the MAP kinase cascade on type I collagen synthesis. Genistein is a tyrosine kinase inhibitor that nonselectively blocks MAP kinase activation, whereas sodium orthovanadate is a tyrosine phosphatase inhibitor that nonselectively upregulates MAP kinase. Genistein (18 µM) increased mesangial cell type I collagen synthesis (170.3 ± 23.0%, expressed as percentage of control values, n = 6, P < 0.001). The ability of genistein to stimulate type I collagen synthesis was not inhibited by a 10-fold excess of ICI-182780 (229.2 ± 28.9% vs. 229.2 ± 22.9%, n = 3, P NS). When cells were exposed to both genistein and estradiol, type I collagen synthesis returned to control levels (98.6 ± 10.6, P NS vs. control, P < 0.001 vs. genistein). Sodium orthovanadate (1 mM) suppressed mesangial cell type I collagen synthesis (63.0 ± 2.8, P < 0.006 vs. control).
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We have previously shown that estradiol suppresses type I and type IV collagen synthesis by cultured murine and rat mesangial cells grown in the presence of serum (17, 19, 25, 29-31). We found that estradiol suppresses mesangial cell type I collagen synthesis by activating the transcription factor AP-1 (29). Upregulation of AP-1 by phorbol esters suppressed mesangial cell type I collagen synthesis, whereas inhibition of AP-1 by curcumin enhanced type I collagen synthesis (29). Estradiol induced a rapid increase in the steady-state message for c-fos, which peaked at 30 min (29). Corresponding to this increase in c-fos mRNA, nuclear proteins from estradiol-treated mesangial cells showed increased binding to an AP-1 consensus sequence oligonucleotide (29). Estradiol-enhanced binding was reversed by cycloheximide and thus dependent on new protein synthesis (29). Curcumin, an inhibitor of AP-1, also reversed the enhanced binding observed in estradiol-treated cells (29). These data led us to conclude that estradiol suppresses mesangial cell type I collagen synthesis by inducing the expression of AP-1 (specifically c-Fos), which in turn binds to AP-1 regulatory motifs to suppress type I collagen gene transcription.
The MAP kinase signaling pathway is a cascade of serine-threonine and tyrosine kinases that convert extracellular stimuli into intracellular responses (3). The MAP kinases ERK1 and ERK2 (p44 MAP kinase and p42 MAP kinase, respectively) are activated by phosphorylation of threonine and tyrosine regulatory sites by MEK, a dual specificity kinase with serine-threonine and tyrosine kinase activity (3). ERK, a proline-directed serine-threonine kinase, translocates from the cytoplasm to the nucleus after activation to phosphorylate ELK-1, which in turn stimulates transcription of c-fos (3, 14). In addition, RSK2, a serine-threonine protein kinase in the p90rsk family, is another substrate for phosphorylation by ERK (26). Activated RSK2 in turn phosphorylates and activates the transcription factor cAMP response element-binding protein, which binds to the c-fos promoter to activate transcription (14).
Estradiol has been shown to activate the MAP kinase pathway in a wide variety of cell types from various species (5, 7, 8, 18, 21, 27, 32). In MCF7 human breast cancer cells, physiological concentrations of estradiol activate c-src, which in turn initiates a cascade of phosphorylation events leading to activation of ERK (21). ERK activation occurs within 2-5 min and completely dissipates within 15-60 min (21). The rapid onset of these effects suggests that they are nongenomic. Activation of MAP kinase by estradiol is not reversed by cycloheximide or actinomycin D and is also induced by a cell membrane-impermeable form of estradiol (8, 32). These effects are thought to be mediated by binding to cell membrane receptors and in most studies are reversed by a specific estrogen-receptor antagonist (7, 21).
Although estradiol upregulates MAP kinase in most cell types, including mesangial cells grown in serum-supplemented medium (described herein), several other patterns of response have been observed. In serum-starved human umbilical vein smooth muscle cells, estradiol has no effect on basal MAP kinase activity but reverses mitogen (endothelin-1 or serum)-stimulated MAP kinase activity (22). Similarly, estradiol inhibits ANG II-induced activation of MAP kinase in serum-starved bovine aortic endothelial cells without affecting basal activity (23). We observed a similar pattern in serum-starved mesangial cells stimulated with PDGF or ANG II but not in cells stimulated with serum itself. A third pattern is seen in human umbilical vein endothelial cells grown in 1% BSA (16). In these cells, estradiol induces a delayed, receptor-mediated increase in MAP kinase activity which peaks at 3 h and is mediated by autocrine production of basic fibroblast growth factor (16).
We hypothesized that estradiol suppresses mesangial cell type I collagen synthesis via activation of the MAP kinase cascade, which in turn upregulates AP-1 activity. This hypothesis was based on the following observations: 1) AP-1 suppresses type I collagen synthesis in murine mesangial cells and mediates the suppressive effects of estradiol on type I collagen synthesis, 2) estradiol stimulates AP-1 activity by upregulating c-fos transcription, 3) c-fos transcription is stimulated by activation of the MAP kinase pathway, and 4) estradiol activates MAP kinase in many other cell types.
We found that physiological concentrations of estradiol activated p44/p42 ERK in murine mesangial cells grown in the presence of serum by specifically increasing the phosphorylated form. Associated with MAP kinase activation, AP-1 activity was increased as reflected by increased binding of nuclear extracts from estradiol-treated cells to an AP-1 oligonucleotide in gel shift assays. We used an inhibitor of the MAP kinase cascade to examine the relationship between this pathway and type I collagen synthesis. PD-98059 is a highly selective inhibitor of MEK1 and MEK2 activation, which interrupts the MAP kinase cascade. PD-98059 does not inhibit activation of other dual specificity protein kinases or other serine-threonine protein kinases (1). We found that blockade of the MAP kinase cascade with PD-98059 suppressed AP-1 activity in gel shift studies and increased type I collagen synthesis by murine mesangial cells. These data suggest that the MAP kinase pathway regulates type I collagen synthesis by modulating AP-1 activity. In addition, PD-98059 reversed the effects of estradiol on AP-1 activity and on collagen I synthesis. These observations suggest that estradiol suppresses type I collagen by activating MAP kinase, which in turn upregulates AP-1 activity.
The poor solubility of PD-98059 in aqueous medium precludes the use of
high concentrations in cell culture experiments (1). In the
concentrations achievable, PD-98059 is only partially effective in
suppressing MAP kinase activation in cells that are exposed to high
concentrations of potent agonists (1). This limited activity explains
why PD-98059 at a concentration of 50 µM merely returned estradiol
(107 M)-suppressed type I
collagen synthesis to control levels, whereas a higher concentration of
PD-98059 was able to raise type I collagen synthesis above control
levels in the presence of a lower concentration of estradiol
(10
9 M).
Consistent with the results we obtained with PD-98059, genistein, a
tyrosine kinase inhibitor that nonselectively blocks MAP kinase
activation, increased mesangial cell type I collagen synthesis, whereas
sodium orthovanadate, a tyrosine phosphatase inhibitor that
nonselectively upregulates MAP kinase, suppressed mesangial cell type I
collagen synthesis. Thus, 17-estradiol activates MAP kinase activity
and suppresses type I collagen synthesis, whereas, genistein, a
plant-derived phytoestrogen, has opposite effects. These differential
actions result from the opposite effects these agents have on tyrosine
kinase activity. Genistein inhibits tyrosine kinase activity by
competitive inhibition of ATP binding to tyrosine kinase via an
estrogen receptor-independent mechanism (2, 20). Our observation that
ICI-182780 reverses the effects of estradiol on type I collagen
synthesis but fails to reverse those of genistein are consistent with
the concept that genistein acts independently of the estrogen
receptor. Other investigators have reported identical effects of
genistein and sodium orthovanadate on type I collagen synthesis in
primary human fetal skin fibroblasts. However, these authors invoked an
entirely different mechanism of action (9).
We also assessed the effects of estradiol on mitogen (PDGF or ANG II)-stimulated MAP kinase activity in serum-starved mesangial cells. We found that in serum-starved cells, estradiol had no effect on basal MAP kinase activity, but reversed the stimulatory effects of PDGF and of ANG II. These data are consistent with our previous observation that estradiol suppresses type I collagen synthesis only in the presence of serum (17), i.e., only in situations where estradiol upregulates MAP kinase activity, and lend further support to our conclusion that estradiol suppresses collagen I synthesis in mesangial cells via activation of MAP kinase.
We are unable to explain why serum modulates the response of MAP kinase to estradiol in murine mesangial cells. The patterns of cellular MAP kinase responses to estradiol described in the literature do not segregate according to whether cells were serum starved or grown in the presence of serum. Some of the studies in which estradiol rapidly stimulated MAP kinase activity were performed in the presence of serum, whereas others were performed in serum-starved cells (5, 7, 8, 18, 21, 32). Studies that found that estradiol inhibited mitogen (ANG II or endothelin 1)-stimulated MAP kinase activity without affecting basal activity were performed using serum-starved cells (22, 23). However, in serum-starved human umbilical vein smooth muscle cells, estradiol antagonized the activation of MAP kinase induced by the addition of serum itself (22).
We postulate that PD-98059 reverses the suppressive effect of estradiol on type I collagen synthesis by blocking estradiol-induced upregulation of the MAP kinase cascade. However, an alternative explanation must be addressed. Growth factor-stimulated phosphorylation of the estrogen receptor at ser118 is required for receptor activation and is mediated by the MAP kinase pathway in some cell types (4, 15). Thus MEK inhibition might reduce ser118 phosphorylation and downregulate estrogen receptor activity. However, in MCF7 cells and in vascular smooth muscle cells, the cell type most closely related to the mesangial cell in phenotype and function, growth factor-stimulated phosphorylation of ser118 is independent of the MAP kinase pathway (12, 13).
Interactions between type I collagen synthesis and the MAP kinase
pathway are cell type- and extracellular stimulus-specific (6, 9, 10,
24). In some cell types, activation of the MAP kinase cascade
stimulates type I collagen transcription (6). In addition, several
studies suggest that ERK plays a role in mediating the transcriptional
activation of type I collagen by transforming growth factor-1 in NIH
3T3 cells and in human mesangial cells (10, 24).
![]() |
FOOTNOTES |
---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: J. Neugarten, Renal Laboratory, Montefiore Medical Center, 111 East 210 St., Bronx, NY 10467.
Received 23 November 1998; accepted in final form 19 July 1999.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Alessi, D. R.,
A. Cuenda,
P. Cohen,
D. T. Dudley,
and
A. R. Saltiel.
PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo.
J. Biol. Chem.
270:
27489-27494,
1995
2.
Barnes, S.,
and
T. G. Peterson.
Biochemical targets of the isoflavone genistein in tumor cell lines.
Proc. Soc. Exp. Biol. Med.
208:
103-108,
1995[Abstract].
3.
Bokemeyer, D.,
A. Sorokin,
and
M. J. Dunn.
Multiple intracellular MAP kinase signaling cascades.
Kidney Int.
49:
1187-1198,
1996[Medline].
4.
Bunone, G.,
P. A. Briand,
R. J. Miksicek,
and
D. Picard.
Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation.
EMBO J.
15:
2174-2183,
1996[Abstract].
5.
Chen, Z.,
I. S. Yuhanna,
Z. Galcheva-Gargova,
R. H. Karas,
M. E. Mendelsohn,
and
P. W. Shaul.
Estrogen receptor mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen.
J. Clin. Invest.
103:
401-406,
1999
6.
Davis, B. H.,
A. Chen,
and
D. W. A. Beno.
Raf and mitogen-activated protein kinase regulate stellate cell collagen gene expression.
J. Biol. Chem.
271:
11039-11042,
1996
7.
Di Domenico, M.,
G. Castoria,
A. Bilancio,
A. Migliaccio,
and
F. Auricchio.
Estradiol activation of human colon carcinoma-derived Caco-2 cell growth.
Cancer Res.
56:
4516-4521,
1996[Abstract].
8.
Endoh, H.,
H. Sasaki,
K. Maruyama,
K. Tayeyama,
I. Waga,
T. Shimizu,
S. Kato,
and
H. Kawashima.
Rapid activation of MAP kinase by estrogen in the bone cell line.
Biochem. Biophys. Res. Commun.
235:
99-102,
1997[Medline].
9.
Greenwel, P.,
W. Hu,
R. A. Kohanski,
and
F. Ramirez.
Tyrosine dephosphorylation of nuclear proteins mimics transforming growth factor beta 1 stimulation of alpha 2 (I) collagen gene expression.
Mol. Cell. Biol.
15:
6813-6819,
1995[Abstract].
10.
Hayashida, T.,
A. Poncelet,
and
H. W. Schhnaper.
Role of extracellular signal-regulated protein kinase (ERK) pathway in 1(1) collagen expression induced by transforming growth factor-
(TGF)-
(Abstract).
J. Am. Soc. Nephrol.
9:
423A,
1998.
11.
Huerre, C.,
C. Junien,
C. Weil,
M. L. Chu,
M. Morabito,
N. van Cong,
J. C. Meyers,
C. Foubert,
M. S. Gross,
D. J. Prockop,
A. Boue,
J. C. Kaplan,
A. de la Chapelle,
and
F. Ramirez.
Human type I procollagen genes are located on different chromosomes.
Proc. Natl. Acad. Sci. USA
79:
6627-6630,
1982[Abstract].
12.
Joel, P. B.,
A. M. Traish,
and
D. A. Lannigan.
Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase.
J. Biol. Chem.
273:
13317-13323,
1998
13.
Karas, R. H.,
E. A. Gauer,
H. E. Bieber,
W. E. Baur,
and
M. E. Mendelsohn.
Growth factor activation of the estrogen receptor in vascular cells occurs via a mitogen-activated protein kinase-independent pathway.
J. Clin. Invest.
101:
2851-2861,
1998
14.
Karin, M.
The regulation of AP-1 activity by mitogen-activated protein kinases.
J. Biol. Chem.
270:
16483-16486,
1995
15.
Kato, S.,
H. Endoh,
Y. Masuhiro,
T. Kitamoto,
S. Uchiyama,
H. Sasaki,
S. Masushige,
Y. Gotoh,
E. Nishida,
H. Kawashima,
D. Metzger,
and
P. Chambon.
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.
Science
270:
1491-1494,
1995[Abstract].
16.
Kim-Schulze, S., Jr.,
W. L. Lowe,
and
W. Schnaper.
Estrogen stimulates delayed mitogen-activated protein kinase activity in human endothelial cells via an autocrine loop that involves basic fibroblast growth factor.
Circulation
98:
413-421,
1998
17.
Kwan, G.,
J. Neugarten,
M. Sherman,
Q. Ding,
U. Fotadar,
J. Lei,
and
S. Silbiger.
Effects of sex hormones on mesangial cell proliferation and collagen synthesis.
Kidney Int.
50:
1173-1179,
1996[Medline].
18.
Lee, H. W.,
and
M. Eghbali-Webb.
Estrogen enhances proliferative capacity of cardiac fibroblasts by estrogen receptor- and mitogen-activated protein kinase dependent pathways.
J. Mol. Cell. Cardiol.
30:
1359-1368,
1998[Medline].
19.
Lei, J.,
S. Silbiger,
F. N. Ziyadeh,
and
J. Neugarten.
Serum-stimulated 1 type IV collagen gene transcription is mediated by TGF-
and inhibited by estradiol.
Am. J. Physiol.
274 (Renal Physiol. 43):
F252-F258,
1998
20.
Levitzki, A.
Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction.
FASEB J.
6:
3275-3282,
1992
21.
Migliaccio, A.,
M. Di Domenico,
G. Castoria,
A. de Falco,
P. Bontempo,
E. Nola,
and
F. Auricchio.
Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells.
EMBO J.
15:
1292-1300,
1996[Abstract].
22.
Morey, A. K.,
A. Pedram,
M. Razandi,
B. A. Prins,
R. M. Hu,
E. Biesiada,
and
E. R. Levin.
Estrogen and progesterone inhibit vascular smooth muscle proliferation.
Endocrinology
138:
3330-3339,
1997
23.
Morey, A. K.,
M. Razandi,
A. Pedram,
R. M. Hu,
B. A. Prins,
and
E. R. Levin.
Oestrogen and progesterone inhibit the stimulated production of endothelin-1.
Biochem. J.
330:
1097-1105,
1998[Medline].
24.
Mucs, I.,
K. L. Skorecki,
and
H. J. Goldberg.
Extracellular signal-regulated kinase and the small GTP-binding protein, Rac, contribute to the effects of transforming growth factor-1 on gene expression.
J. Biol. Chem.
271:
16567-16572,
1996
25.
Neugarten, J.,
and
S. Silbiger.
Effects of sex hormones on mesangial cells.
Am. J. Kidney Dis.
26:
147-151,
1995[Medline].
26.
Prueksaritanont, T.,
M. A. Correia,
A. E. Rettie,
D. C. Swinney,
P. E. Thomas,
and
L. Z. Benet.
Cyclosporine metabolism by rat liver microsomes.
Drug Metab. Dispos.
21:
730-737,
1993[Abstract].
27.
Ruzycky, A. L.
Effects of 17-estradiol and progesterone on mitogen-activated protein kinase expression and activity in rat uterine smooth muscle.
Eur. J. Pharmacol.
300:
247-254,
1996[Medline].
28.
Satriano, J.,
and
D. Schlondorff.
Activation and attenuation of transcriptikon factor NF-KB in mouse glomerular mesangial cells in response to tumor necrosis factor-, immunoglobin G and adenosine 3': 5'-cyclic monophosphate. Evidence for involvement of reactive oxygen species.
J. Clin. Invest.
94:
1629-1636,
1994[Medline].
29.
Silbiger, S.,
J. Lei,
and
J. Neugarten.
Estradiol suppresses type I collagen synthesis by mesangial cells via activation of AP-1.
Kidney Int.
55:
1268-1276,
1998.
30.
Silbiger, S.,
J. Lei,
F. N. Ziyadeh,
and
J. Neugarten.
Estradiol reverses TGF-1-stimulated type IV collagen gene transcription in murine mesangial cells.
Am. J. Physiol.
274 (Renal Physiol. 43):
F1113-F1118,
1998
31.
Silbiger, S.,
and
J. Neugarten.
The impact of gender on the progression of chronic renal disease.
Am. J. Kidney Dis.
25:
515-533,
1995[Medline].
32.
Watters, J. J.,
J. S. Campbell,
M. J. Cunningham,
E. G. Krebs,
and
D. M. Dorsa.
Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription.
Endocrinology
138:
4030-4033,
1997